Different versions of Atrasentan and selection recommendations

Atrasentan (atrasentan) is a relatively newly launched innovative drug for kidney diseases globally, so it is significantly different from traditional kidney disease drugs in terms of supply, price and generic drug coverage. At present, this product has been approved in China, but due to the short time it has been officially launched, it is temporarily unavailable in hospitals or pharmacies in China, which forces many patients to pay attention to overseas supply channels. The most common specification in overseas markets is 0.75mg*30 tablets. Public prices in recent years show that the price per box is more than 13,000 US dollars, making it a typical "high-cost innovative drug".

Since there is no generic version of atrasentan approved by any country, only the original version is on the market whether in the United States, Europe, Japan or Southeast Asia. Therefore, there is almost no competitive factor in market prices, resulting in the overall cost of purchasing drugs remaining at a high level. For patients with primary immunoglobulin A nephropathy who need long-term control of proteinuria and delaying the deterioration of renal function, cost pressure often becomes an important factor in deciding whether to use it long-term.

When choosing a version, patients need to pay attention to three key points: first, the drugs must be from original research sources and avoid "irregular imitations" that have not received regulatory approval; second, attention should be paid to the cold chain, transportation and packaging integrity of the drugs; third, priority should be given to platforms or overseas medical institutions with legal prescription issuance and cross-border pharmaceutical service qualifications. Since atrasentan is a long-term treatment drug, standardizing channels is particularly critical.

From the perspective of usage recommendations, if the patient's condition is characterized by persistently elevated proteinuria, poor conventional treatment results, and financial conditions, the patient can consider purchasing the drug through formal channels under the guidance of a doctor; if the cost is too high or follow-up conditions are limited, it is usually necessary to evaluate alternatives, such as optimizingRAS blocking treatment or selecting other drugs related to the IgAN mechanism according to guidelines.

Reference materials:https://www.vanrafia.com/